Skip to main content

Blood-Based Biomarkers for Alzheimers and Parkinsons Disease

  • 1st Edition, Volume 191 - December 1, 2026
  • Latest edition
  • Editor: Subashchandrabose Chinnathambi
  • Language: English

Blood-Based Biomarkers for Alzheimer’s and Parkinson’s Disease, Volume 191 in the International Review of Neurobiology series, presents current advances and comprehensive r… Read more

Description

Blood-Based Biomarkers for Alzheimer’s and Parkinson’s Disease, Volume 191 in the International Review of Neurobiology series, presents current advances and comprehensive reviews on the development and application of circulating biomarkers in neurodegenerative disorders. It brings together contributions from an international panel, highlighting emerging strategies for early detection, diagnosis, and monitoring of Alzheimer’s and Parkinson’s diseases. Chapters explore a wide range of topics, including the Diagnostic Potential of Exosomes in Neurodegenerative Diseases and Cancer, Blood Biomarkers of Oxidative Stress and Mitochondrial Dysfunction in Alzheimer’s and Parkinson’s Diseases, GFAP and the Genetic Code of Astrocyte Activation in Alzheimer’s Disease, and much more.

Additional chapters cover Blood-Based Emerging Biomarkers in Early Detection and Diagnosis of Alzheimer’s Disease, Advances in Nanomaterial-Based Biomarker Detection for Neurodegenerative Diseases, Blood-Based Biomarkers in Alzheimer’s and Parkinson’s Disease: From Molecular Pathology to Therapeutic Potential, Blood-Based Biomarkers and Their Role in AD/PD Diagnosis, The Emerging Landscape of Circulatory Biomarkers in Alzheimer’s Disease, Biofluid-Based Biosensors, Biomarkers of Vascular Dementia and Alzheimer’s Disease, Silent Clues in Blood: Proteomic Approach for Alzheimer’s Disease, and more.

Key features

  • Presents current advances in blood-based biomarkers for Alzheimer’s and Parkinson’s diseases
  • Includes contributions from leading experts in neuroscience, biomarker research, and clinical neurobiology
  • Covers diverse biomarker types, including exosomes, proteomics, neurofilament light chain, and biosensors
  • Explores emerging diagnostic technologies and clinical translation of non-invasive biomarkers
  • Serves as an essential reference for researchers, clinicians, and graduate students

Readership

Undergraduates, graduates, academics, and researchers in the field of Adenosine A2A Receptor Antagonists

Table of contents

1. Diagnostic Potential of Exosomes in Neurodegenerative Diseases and Cancer

2. Blood Biomarkers of Oxidative Stress and Mitochondrial Dysfunction in Alzheimer’s and Parkinson’s Diseases

3. GFAP and the Genetic Code of Astrocyte Activation in Alzheimer’s Disease

4. Blood-Based Emerging Biomarkers in Early Detection and Diagnosis of Alzheimer’s Disease

5. Advances in Nanomaterial-Based Biomarker Detection for Neurodegenerative Diseases

6. Blood-Based Biomarkers in Alzheimer’s and Parkinson’s Disease: From Molecular Pathology to Therapeutic Potential

7. Blood-Based Biomarkers and Their Role in AD/PD Diagnosis

8. The Emerging Landscape of Circulatory Biomarkers in Alzheimer’s Disease

9. Biofluid-Based Biosensors

10. Biomarkers of Vascular Dementia and Alzheimer’s Disease

11. Silent Clues in Blood: Proteomic Approach for Alzheimer’s Disease

12. Blood-Based Biomarkers for Alzheimer’s Disease: Advances in Early Diagnosis and Clinical Translation

13. Microbiome, Epilepsy, and the Role of Probiotics in Mitigating Epilepsy

14. The Clinical Utility of Blood-Based Biomarkers of Alzheimer’s Disease: Triumphs and Pitfalls

15. Neurofilament Light Chain (NfL) as a Biomarker for Neurodegeneration: Protein Biology, Detection Methods, and Clinical Applications

16. Effect of Dietary Pattern on Biomarkers in Alzheimer’s Disease

17. Circulating Biochemical Signatures of Neurodegeneration in Alzheimer’s Disease

18. Peripheral Manifestations of Nigrostriatal Neurodegeneration in Parkinson’s Disease

Product details

  • Edition: 1
  • Latest edition
  • Volume: 191
  • Published: December 1, 2026
  • Language: English

About the editor

SC

Subashchandrabose Chinnathambi

Subashchandrabose Chinnathambi is Additional Professor at the Department of Neurochemistry, National Institute of Mental Health and Neurosciences Hospital Bangalore, Karnataka, India. His scientific interests include physiopathology of neurodegenerative disorders, Tau Cytoskeleton, Tau-GPCR, purinergic and chemokine receptors, Tau stem cells, animal models, neuropharmacology, therapeutic approaches targeting Tau oligomers, and biomarkers for neurodegeneration. He serves on the editorial board for various international cell biology journals and is also a regular invited speaker at a number of meetings and workshops. Dr. Chinnathambi has more than 16 years of research experience in the area of neuroscience and Tau-related research in Alzheimer’s Disease.

Affiliations and expertise
Additional Professor, Department of Neurochemistry, National Institute of Mental Health and Neurosciences Hospital Bangalore, Karnataka, India